

500 1624

## **PATENT**

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Mark E. Fraley

Serial No.:

10/540,784

Case No.: 21301P

Art Unit 1624

Filed:

June 8, 2005

For:

Tyrosine Kinase Inhibitors

Auth. Off.:

S. Moore

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## RESPONSE TO RESTRICTION REQUIREMENT

Sir:

This paper is filed in response to the restriction requirement mailed December 21, 2007 and for which a response is due on January 21, 2008. Claims 1-36 are currently pending in the application and are subject to the following restriction under 35 U.S.C. 121:

Group I, claims 1-9, drawn to compounds of formula (1), wherein  $R^4$ =cyclic group and  $R^2$ ,  $R^3$  and  $R^5$  = hydrogen and compositions thereof.

Group II, claims 10-17 and 19 drawn to method of preventing and treating cancer, angiogenesis, retinal vascularization, diabetic retinopathy, age related macular degeneration and retinal ischemia with compounds of formula (1).

Group III, claims 30 and 31, drawn to a method of preventing and treating cancer with complex compositions in combination with compounds of formula (1).

Group IV, claim(s) 1-4 and 6-9, drawn to compounds of formula (1) not covered in Group (1) and compositions thereof.